Stocktoria
ABVC BIOPHARMA, INC. ABVC
ABVC BIOPHARMA, INC. (ABVC) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $296,000 at a -2671.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.174 |
| Retained earnings / assets | -3.649 |
| EBIT / assets | -0.34 |
| Equity / liabilities | 1.713 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ABVC | ABVC BIOPHARMA, INC. | 3/9 | -13.52 | — | — |
| HIND | Vyome Holdings, Inc | 3/9 | — | — | — |
| ALLR | Allarity Therapeutics, Inc. | 3/9 | — | — | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 2/9 | — | — | — |
| CLNN | Clene Inc. | 1/9 | — | — | — |
| IBIO | iBio, Inc. | 3/9 | — | — | — |
| MNOV | MEDICINOVA INC | 1/9 | -18.54 | — | — |
About ABVC BIOPHARMA, INC.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
FAQ
Is ABVC financially healthy?
ABVC BIOPHARMA, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ABVC pay a dividend?
No, ABVC BIOPHARMA, INC. does not currently pay a dividend.
How profitable is ABVC?
In FY2025, ABVC BIOPHARMA, INC. had a net margin of -2671.8% and a return on equity of -59.5%.
Is ABVC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ABVC BIOPHARMA, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.